Lenk L, Baccelli I, Laqua A, Heymann J, et al. The IL-7R antagonist lusvertikimab reduces leukemic burden in xenograft ALL via antibody-dependent cellular phagocytosis. Blood 2024;143:2735-2748.
PMID: 38518105